ATTO logo

Attovia Therapeutics, Inc.

ATTO
Healthcare|Biotechnology|US
$15.27
+0.27 (+1.80%)
DCF Value
$0.98
Tangible Book / Share
$2.47
Cash / Share
$2.52
Next Earnings Report
Dec 2, 2026
EPS est. -$0.56 · Revenue est. $450.0K
Financing Filings (last 12 months)
4
Shelf registrations / offering prospectuses — latest Aug 5, 2026 (424B4). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis
Nov 5, 2026 · GlobeNewsWire
Attovia Therapeutics to Participate in Upcoming Investor Conferences
Oct 27, 2026 · GlobeNewsWire
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
Sep 28, 2026 · GlobeNewsWire
Attovia Therapeutics to Participate in Upcoming Investor Conferences
Sep 3, 2026 · GlobeNewsWire
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Sep 2, 2026 · GlobeNewsWire

SEC Filings (16)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Sep 2, 202610-QQuarterly reportDocumentIndex
Sep 2, 20268-KMaterial eventDocumentIndex
Aug 12, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 11, 2026SC 13DActivist / 5%+ stakeDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Aug 6, 2026S-8Employee stock planDocumentIndex
Aug 5, 2026424B4Offering prospectusDocumentIndex
Aug 4, 2026EFFECTDocumentIndex
Aug 4, 2026CERTDocumentIndex
Aug 4, 2026S-1/AIPO / offering registrationDocumentIndex
Jul 29, 20268-A12BDocumentIndex
Jul 29, 2026S-1/AIPO / offering registrationDocumentIndex
Jul 14, 2026S-1IPO / offering registrationDocumentIndex
Jun 5, 2026DRS/ADocumentIndex
Feb 12, 2026DRS/ADocumentIndex
Dec 19, 2025DRSDocumentIndex